Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.82 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CASR | P41180 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTR1E | P28566 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26804107 | 0.91 | SLC6A3 (0.82) | SLC6A3EPHX2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL26804110 | 0.85 | SLC6A3 (0.78) | SLC6A3EPHX2CASRKMT2A | |
| SCHEMBL21682973 | 0.84 | SLC6A3 (1.00) | SLC6A3RAB9ACASRMAPTKMT2A | |
| SCHEMBL26804101 | 0.84 | SLC6A3 (0.78) | SLC6A3CASRKMT2A | |
| SCHEMBL26804098 | 0.83 | SLC6A3 (0.85) | SLC6A3CASRKMT2A | |
| SCHEMBL26804142 | 0.83 | SLC6A3 (0.67) | SLC6A3CASR | |
| SCHEMBL23902831 | 0.83 | SLC6A3 (1.00) | SLC6A3CASR | |
| SCHEMBL26804104 | 0.82 | SLC6A3 (0.74) | SLC6A3CASRMEN1MAPTKMT2A | |
| SCHEMBL26804134 | 0.81 | SLC6A3 (0.78) | SLC6A3CASRMEN1MAPTKMT2A | |
| SCHEMBL26804108 | 0.79 | SLC6A3 (0.75) | SLC6A3EPHX2CASRMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TFEB, TP53, BECN1 | SLC6A3 2908/4885EPHX2 4641/4885RAB9A 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.